Publications
- Nivolumab plus chemotherapy or ipilimumab in the first-line palliative therapy of esophageal, gastroesophageal junction, and gastric cancer2023 | Faculty of Medicine in Hradec Králové
- Prognostic value of blood cell count-derived ratios in BRAF-mutated metastatic melanoma2022 | Faculty of Medicine in Hradec Králové
- Adverse effects of combination immunotherapy in renal cancer, lung cancer, and melanoma +12022 | Faculty of Medicine in Hradec Králové
- Administration of Nivolumab in Metastatic Renal Cell Cancer Following Treatment With mTOR Inhibitors2021 | Faculty of Medicine in Hradec Králové, First Faculty of Medicine
- Adjuvant therapy of malignant melanoma: general and practical experience2021 | Faculty of Medicine in Hradec Králové
- Risk Factors for Infections, Antibiotic Therapy, and Its Impact on Cancer Therapy Outcomes for Patients with Solid Tumors2021 | Faculty of Medicine in Hradec Králové
- How to manage side effects of immunotherapy How to manage side effects of immunotherapy2020 | Faculty of Medicine in Hradec Králové
- Real-accesible novelties in immunotherapy from the perspective of a medical oncologist working in the Czech Republic2020 | Faculty of Medicine in Hradec Králové
- Complete remission of metastatic malignant melanoma treated with nivolumab, complicated with pulmonary toxicity2018 | Faculty of Medicine in Hradec Králové
- Pembrolizumab in pretreated patient2018 | Faculty of Medicine in Hradec Králové
Loading network view...